Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease
Identifieur interne : 002F93 ( Main/Exploration ); précédent : 002F92; suivant : 002F94Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease
Auteurs : Vincent Paille [France] ; Philippe Brachet [France] ; Philippe Damier [France]Source :
- Neuroreport : (Oxford) [ 0959-4965 ] ; 2004.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Animal, Animal model, Animals, Antiparkinson Agents (pharmacology), Behavior, Animal (drug effects), Behavior, Animal (physiology), Cell Count, Cell death, Chronic, Development, Dopamine, Dopaminergic neuron, Dyskinesia, Dyskinesias (physiopathology), Human, Immunohistochemistry, Involuntary movement, Lesion, Levodopa, Levodopa (pharmacology), Locus niger, Male, Motor control, Oxidopamine, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (pathology), Parkinson Disease, Secondary (physiopathology), Parkinson disease, Pathogenesis, Rat, Rats, Rats, Sprague-Dawley, Substantia Nigra (pathology), Substantia Nigra (physiopathology), Sympatholytics, Tyrosine 3-Monooxygenase (metabolism).
- MESH :
- chemical , metabolism : Tyrosine 3-Monooxygenase.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Behavior, Animal.
- pathology : Parkinson Disease, Secondary, Substantia Nigra.
- physiology : Behavior, Animal.
- physiopathology : Dyskinesias, Parkinson Disease, Secondary, Substantia Nigra.
- Animals, Cell Count, Immunohistochemistry, Male, Oxidopamine, Rats, Rats, Sprague-Dawley, Sympatholytics.
Abstract
The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000D78
- to stream PascalFrancis, to step Curation: 000656
- to stream PascalFrancis, to step Checkpoint: 000C15
- to stream Main, to step Merge: 003415
- to stream PubMed, to step Corpus: 001034
- to stream PubMed, to step Curation: 000F93
- to stream PubMed, to step Checkpoint: 000F93
- to stream Ncbi, to step Merge: 000436
- to stream Ncbi, to step Curation: 000436
- to stream Ncbi, to step Checkpoint: 000436
- to stream Main, to step Merge: 003229
- to stream Main, to step Curation: 002F93
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</title>
<author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paille">Vincent Paille</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Clinique Neurologique and Centre d'Investigation Clinique, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0446932</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0446932 INIST</idno>
<idno type="RBID">Pascal:04-0446932</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D78</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000656</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000C15</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000C15</idno>
<idno type="wicri:doubleKey">0959-4965:2004:Paille V:role:of:nigral</idno>
<idno type="wicri:Area/Main/Merge">003415</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15094523</idno>
<idno type="wicri:Area/PubMed/Corpus">001034</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001034</idno>
<idno type="wicri:Area/PubMed/Curation">000F93</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F93</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F93</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F93</idno>
<idno type="wicri:Area/Ncbi/Merge">000436</idno>
<idno type="wicri:Area/Ncbi/Curation">000436</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000436</idno>
<idno type="wicri:doubleKey">0959-4965:2004:Paille V:role:of:nigral</idno>
<idno type="wicri:Area/Main/Merge">003229</idno>
<idno type="wicri:Area/Main/Curation">002F93</idno>
<idno type="wicri:Area/Main/Exploration">002F93</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</title>
<author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paille">Vincent Paille</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Clinique Neurologique and Centre d'Investigation Clinique, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroreport : (Oxford)</title>
<title level="j" type="abbreviated">Neuroreport : (Oxf.)</title>
<idno type="ISSN">0959-4965</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroreport : (Oxford)</title>
<title level="j" type="abbreviated">Neuroreport : (Oxf.)</title>
<idno type="ISSN">0959-4965</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Animal model</term>
<term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Behavior, Animal (drug effects)</term>
<term>Behavior, Animal (physiology)</term>
<term>Cell Count</term>
<term>Cell death</term>
<term>Chronic</term>
<term>Development</term>
<term>Dopamine</term>
<term>Dopaminergic neuron</term>
<term>Dyskinesia</term>
<term>Dyskinesias (physiopathology)</term>
<term>Human</term>
<term>Immunohistochemistry</term>
<term>Involuntary movement</term>
<term>Lesion</term>
<term>Levodopa</term>
<term>Levodopa (pharmacology)</term>
<term>Locus niger</term>
<term>Male</term>
<term>Motor control</term>
<term>Oxidopamine</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (pathology)</term>
<term>Parkinson Disease, Secondary (physiopathology)</term>
<term>Parkinson disease</term>
<term>Pathogenesis</term>
<term>Rat</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Substantia Nigra (pathology)</term>
<term>Substantia Nigra (physiopathology)</term>
<term>Sympatholytics</term>
<term>Tyrosine 3-Monooxygenase (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease, Secondary</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Behavior, Animal</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesias</term>
<term>Parkinson Disease, Secondary</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Count</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Oxidopamine</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Sympatholytics</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lésion</term>
<term>Modèle animal</term>
<term>Pathogénie</term>
<term>Lévodopa</term>
<term>Neurone dopaminergique</term>
<term>Mort cellulaire</term>
<term>Oxidopamine</term>
<term>Locus niger</term>
<term>Dyskinésie</term>
<term>Chronique</term>
<term>Mouvement involontaire</term>
<term>Parkinson maladie</term>
<term>Dopamine</term>
<term>Développement</term>
<term>Rat</term>
<term>Homme</term>
<term>Animal</term>
<term>Contrôle moteur</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Pays de la Loire</li>
</region>
<settlement><li>Nantes</li>
</settlement>
</list>
<tree><country name="France"><region name="Pays de la Loire"><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paille">Vincent Paille</name>
</region>
<name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
<name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:04-0446932 |texte= Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |